# Junta clínica — PT-pseudo_2b3ef1d3a505 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_2b3ef1d3a505",
  "pid": "PT-pseudo_2b3ef1d3a505",
  "task": 1,
  "psa": 4.2,
  "age": 67,
  "months": 2,
  "pirads": "5",
  "psad": 0.06,
  "psav": 0.66,
  "psap": 3.7,
  "vol": 69.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.81166416,
  "medhx": "COPD",
  "meds": "tiotropium, salbutamol PRN",
  "notes": "PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.",
  "pmhx": [
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "66 kg",
    "height": "185 cm",
    "bmi": "19.3",
    "bp": "113/72 mmHg",
    "hr": "74 bpm",
    "smoking": "Ex-smoker (30 pack-yr, quit 2015)",
    "last_dental": "3 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "23 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review."
    },
    {
      "s": "History",
      "t": "A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent."
    }
  ],
  "occupation": "mechanical engineer",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Nephew",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Pulmonary function test — known COPD follow-up",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "31 units / week (heavy)",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 9/35 (moderate LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2b3ef1d3a505
Task: 1

Encounter: Urology - outpatient on 23 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.06 ng/mL²
  - PSA velocity: 0.66 ng/mL/yr
  - Prior PSA: 3.7 ng/mL
  - Prostate volume: 69.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81166416 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.

Vitals: weight 66 kg, height 185 cm, BMI 19.3, BP 113/72 mmHg, HR 74 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2015).

Chief complaint: Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review.

History: A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 31 units / week (heavy); exercise Light weight-training at home, 2x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.35
  uncertainty  +/- 0.15 epistemic (95% band 0.05-0.65); among patients I cannot tell apart the outcome was 0.93 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.36: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."
  2. distance 1.61: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"
  3. distance 1.68: PI-RADS 5, PSA 8.3, PSAD 0.215, age 66, DRE Suspicious -> DEFER (clear). He wrote: "This person should discuss curative treatment (younger patient with palpable, MRI-visible high-risk disease incl Gleason 5 findings). If not curative treatment for any r…"

PRECEDENT: DEFER (weighted vote 0.32 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines discuss the use of MRI and biopsy in the context of prostate cancer risk stratification. The guideline states that a PI-RADS score of 3 or higher mandates a biopsy. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your suggestion of no biopsy is not decisive because the guideline mandates a biopsy for PI-RADS 5 lesions. EXPERT-COHORT, the cohort criterion is insufficient because the guideline emphasizes that the documented grade of the prior biopsy and surveillance history are key, which the panel alone does not resolve.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the ISUP Grade Group 1 result from the earlier biopsy means the guideline does not mandate a repeat biopsy based on the prior result alone, but the current PI-RADS 5 score does.
radiology_report - the PI-RADS 5 score mandates a biopsy according to the guideline, meaning the finding itself is decisive.
psa_trend - the PSA velocity of 0.66 ng/mL/yr is a variable that the guideline does not explicitly use as a primary decision point in this context.
laboratory_results - the PSA density of 0.06 ng/mL/cc is a variable that the guideline uses in risk-adapted matrices to guide the decision.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the PI-RADS 5 finding mandates a repeat biopsy according to EAU guidelines, given the prior positive biopsy result.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the PI-RADS 5 score mandate a biopsy according to the EAU guidelines?
  psa_trend (get_psa_trend) -> Does the PSA velocity of 0.66 ng/mL/yr influence the decision?
  previous_notes (get_previous_notes) -> What is the ISUP Grade Group 1 result from the earlier biopsy, and what is the current surveillance protocol status?
  laboratory_results (get_lab_results) -> Does the PSA density of 0.06 ng/mL/cc influence the decision?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the ISUP Grade Group 1 result from the earlier biopsy, and what is the current surveillance protocol status?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Does the PI-RADS 5 score mandate a repeat biopsy according to the EAU guidelines?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: PI-RADS 5 lesion in the right mid-peripheral zone.

psa_trend
Does the PSA velocity of 0.66 ng/mL/yr influence the decision?
The PSA velocity of 0.66 ng/mL/yr is a variable that the guideline does not explicitly use as a primary decision point in this context.

previous_notes
Q1. What is the ISUP Grade Group 1 result from the earlier biopsy, and what is the current surveillance protocol status?
The ISUP Grade Group 1 result from the earlier biopsy is not explicitly stated in the retrieved notes, and the current surveillance protocol status is not explicitly stated.

laboratory_results
Does the PSA density of 0.06 ng/mL/cc influence the decision?
The PSA density of 0.06 ng/mL/cc is a variable that the guideline uses in risk-adapted matrices to guide the decision.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided the necessary context regarding prior biopsy results and surveillance.

WHAT THIS SUPPORTS
FOR sampling this patient now
radiology_report: PI-RADS 5 score mandates a biopsy according to the EAU guidelines.
laboratory_results: The PSA density of 0.06 ng/mL/cc is a variable that the guideline uses in risk-adapted matrices to guide the decision.

AGAINST sampling this patient now
previous_notes: The ISUP Grade Group 1 result from the earlier biopsy is not explicitly stated, leaving the prior result ambiguous.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 4.20 ng/mL over 4 points spanning 19 months; velocity +1.58 ng/mL per year; doubling time about 12 months.
PROJECTION at 6 months: 6.5 ng/mL, conformal 95% band 1.9-22.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.36
  uncertainty  +/- 0.16 epistemic (95% band 0.06-0.67), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.35  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.36  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.32  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.36 — carried by weighted panel.
PANEL ANSWER: NO BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the Registrar answered the moderator's questions to the extent that they revealed missing information. Specifically, the `previous_notes` indicated that the ISUP Grade Group 1 result and the current surveillance protocol status were not explicitly stated.

ALIGNMENT WITH THE PANEL
The retrieved evidence leans toward biopsy, as the `radiology_report` indicated a PI-RADS 5 score mandates a biopsy per EAU guidelines, and the `laboratory_results` showed a PSA density of 0.06 ng/mL/cc, which is a variable used in risk-adapted matrices. This finding contradicts the PANEL-PROTOCOL's final answer of NO BIOPSY.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the ISUP Grade Group 1 result from the earlier biopsy, and what is the current surveillance protocol status? This question remains unanswered, as the `previous_notes` explicitly stated this information was not explicitly recorded.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS 5 score from the `radiology_report` is highly relevant because the EAU guideline explicitly mandates a biopsy for this finding. The lack of the prior biopsy grade from the `previous_notes` is critical because the PANEL-PROTOCOL explicitly noted that the absence of this documented prior grade led to the trained experts deciding against biopsy.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy based on the PI-RADS 5 finding and the EAU guideline mandate, despite the ambiguity regarding the prior biopsy result.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: borderline)

67y/PSA 4.2/PSAD 0.06, PI-RADS 5, prior positive biopsy, no prior ISUP grade recorded. PI-RADS 5 mandates biopsy per guidelines, but prior positive status and lack of grade documentation weigh against immediate repeat sampling. Re-image in two years with low threshold for biopsy is the alternative plan.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
